glp 1 drugs and blood clots A recent study suggests that GLP-1 medications, commonly prescribed for managing diabetes obesity, may also lower the risk of dangerous clots. The study's lead author, Dr. Rushad Patell of Beth GLP-1 Therapies May Benefit MPN

And, as always, a new drug comes with some caveats and tradeoffs

Tirzepatide, currently recognized as the most effective dual-agonist therapy, targets GLP-1 and GIP receptors but lacks the glucagon component that enhances retatrutide's metabolic impact

4 Characterization of CNS GIPR Knockout mice

It absorbs and stores glucose from the bloodstream, which is critical for insulin sensitivity

Shadyab et al., J Gerontol 2025 4

While this study was only performed in relatively lean female mice, which are mostly protected against diet-induced obesity, it is in line with a study performed in patients receiving tirzepatide, dulaglutide, or placebo, which showed that tirzepatide treatment dose-dependently decreased levels of ApoC-III and ApoB and the number of large triglyceride-rich lipoprotein particles and small LDL particles, suggesting a net improvement in atherogenic lipoprotein profile (Wilson et al